Essential Thrombocythemia Treatments
Find Essential Thrombocythemia Treatments
Medications for Essential Thrombocythemia
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Essential Thrombocythemia.
Found 2 Approved Drugs for Essential Thrombocythemia
Agrylin
Generic Name
Anagrelide
Agrylin
Generic Name
Anagrelide
Form: Capsule
Method of administration: Oral
FDA approval date: March 14, 1997
Classification: Platelet-reducing Agent
Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )
Vonjo
Generic Name
Pacritinib
Vonjo
Generic Name
Pacritinib
Form: Capsule
Method of administration: Oral
FDA approval date: February 28, 2022
Classification: Kinase Inhibitor
VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies (1.
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances